GlassScriptPhysician profile
Nicholas Franssen
NPI 1043610017
$3,489.33
in general payments reported to CMS, 2019-2025
34 companies · $586 in 2025
The $586 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $698 · 2023: $794 · 2024: $800 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.79 | 2021-2025 | |
| Amgen INC. | $353.63 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $247.26 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $206.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.45 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $148.74 | 2023-2025 | Veozah |
| Lilly USA, LLC | $116.28 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $111.57 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.39 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $87.33 | 2023-2025 | Invega Sustenna, Spravato |
| Merck Sharp & Dohme LLC | $65.40 | 2022-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.67 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $54.74 | 2022-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $54.38 | 2023-2025 | Opsumit, Uptravi |
| Medtronic, INC. | $52.79 | 2024-2025 | Symplicity G3, Kyphon Express II Kyphopak Tray |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $52.74 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.65 | 2023-2024 | Xifaxan |
| Boston Scientific Corporation | $46.28 | 2022-2023 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $37.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $34.08 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $33.30 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $31.85 | 2021-2022 | |
| Esperion Therapeutics, INC. | $29.04 | 2021 | |
| Dexcom, INC. | $21.61 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.75 | 2024 | |
| Almatica Pharma LLC | $16.87 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $16.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.31 | 2021 | |
| Ascensia Diabetes Care US INC. | $16.08 | 2024 | |
| Corcept Therapeutics | $14.56 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $14.31 | 2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $12.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Franssen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.